The National Medical Products Administration (NMPA) of China has officially approved Tibremciclib Capsules (BPI-16350, brand name Kangmeina) developed by Betta Pharmaceuticals. ✅ This innovative Class 1 drug is indicated in combination with fulvestrant for adult…
China’s National Medical Products Administration (NMPA) has officially approved Luvometinib Tablets (brand name Fumaining®, development code FCN-159), an innovative Class 1 new drug developed by Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ✨ The approval was granted…
Recently, Fujian Shengdian Pharmaceutical Co., Ltd., a subsidiary of Hengrui Medicine, received approval from the National Medical Products Administration (NMPA) for the launch of Fosrolapitant and Palonosetron Hydrochloride Injection. 💊 This novel Class 1 innovative…
How strong is China innovative drug industry? The answer is increasingly evident as the nation now contributes nearly one-third of all drug candidates under development worldwide. China’s innovative drug industry is rising at unprecedented speed,…
May 29, 2025 — The National Medical Products Administration (NMPA) has granted conditional approval through a priority review pathway for Zanidatamab Injection (brand name: ZIIHERA), developed by BeiGene (Suzhou) Biologics Co., Ltd. 👉 The medication…
China’s National Medical Products Administration (NMPA) has officially approved Inpegsomatropin Injection, a first-in-class, innovative long-acting growth hormone developed by Xiamen Amoytop Biotech Co., Ltd., for the treatment of growth hormone deficiency (GHD) in children aged…
The National Medical Products Administration (NMPA) has officially approved the Class 1 innovative drug Trastuzumab Rezetecan Injection (brand name Aiweida). The drug was independently developed by Suzhou Suncadia Biopharma Co., Ltd. 👉 It is approved…
Source: DengYueMed On October 18, Chen Yuqing, Chairman of Fosun Pharma, stated at an event that China’s innovative drug industry has made a qualitative leap over the past decade. Since 2014, China’s share of global…
China’s Pharmaceutical Innovation Goes Global: Challenges and New Momentum In the first five months of 2025, China’s outbound innovative drug licensing deals have exceeded USD 45 billion, almost equaling the total for all of 2024.…
On May 6, the U.S. government announced plans to unveil new pharmaceutical tariff measures within the next two weeks. Can innovative drugs accelerate overseas expansion by 2025? Under current U.S. policy, pharmaceuticals are classified as…
In the first half of 2025, China’s innovative drug license-out deals surpassed USD 15 billion, marking a 40% year-over-year increase. Antibody-drug conjugates (ADCs) and bispecific antibodies now account for over 60% of all outbound transactions…
Guangdong, China — May 22, 2025 丨 The National Medical Products Administration (NMPA) has officially approved Onradivir Tablets, a Class 1 innovative drug developed by Guangdong Raynovent Biotechnology Co., Ltd. for the treatment of adult…
